Testimonials highlight opportunities for China cross-border collaboration

April 25, 2017

Cross-border partnerships are the focus of new rules just proposed by the China FDA that will improve upon commercial opportunities to get drug approvals in China. At the same time, the changes will make international collaboration and investment easier, including foreign-approved IND exemptions that  speed up drug trials by two years or more and expedited regulatory processes for new drugs and IND/CTA approvals for certain indications to go to clinical trial, among other highlights. China continues to be the world’s fastest growing healthcare market with investment potential increasing each year. There is no better time to forge cross-border partnerships with China-based drug development companies.


The ninth annual ChinaBio® Partnering Forum is the largest and most productive life science partnering conference in China, held May 31–June 1 in Zhuhai, China. The event is expected to attract over 900 leaders from across the life science value chain from global pharma and biotech companies to innovative startups and researchers from leading universities and institutes, as well as VCs and other investors. Watch these video testimonials and find out more or register to attend.

Previous Video
BIO-Europe Spring® 2017: Avir BD execs on innovative meds for Canadians
BIO-Europe Spring® 2017: Avir BD execs on innovative meds for Canadians

Located in Quebec, Canada, Avir Pharma, a specialty pharma company, is part of the Laboratoire Riva group. ...

Next Video
BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs
BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs

Dr. Kevin Cox, CEO of Imanova, the UK-based translational biomedical imaging company, explains to Scrip’s M...